Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 223 member A (FAM223A) is a long intergenic non-coding RNA (lincRNA) gene, classified as non-protein coding and sometimes referenced as a possible pseudogene or lncRNA. It does not encode a protein and does not belong to established therapeutic target classes such as receptor, enzyme, transporter, or transcription factor. FAM223A is transcribed into a non-coding RNA over 200 nucleotides, and while the precise biological roles of this specific lincRNA are not well characterized, lincRNAs in general are known to participate in the regulation of chromatin organization, gene expression in cis or trans, stabilization of RNA molecules, and acting as molecular scaffolds or decoys. Current data do not identify FAM223A as having direct roles in recognized disease pathways, biomarker signatures, drug interactions, or targeted therapeutic mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 223 member A (non-protein coding) (FAM223A).